Department of Hepatology, Qilu Hospital of Shandong University, Wenhuaxi Road 107#, Jinan, 250012, Shandong, China.
Hepatology Institute of Shandong University, Jinan, 250012, China.
Clin Epigenetics. 2023 May 6;15(1):79. doi: 10.1186/s13148-023-01495-9.
Glucocorticoids could greatly improve the prognosis of patients with acute-on-chronic hepatitis B liver failure (ACHBLF). Suppressor of cytokine signaling (SOCS) 1 methylation has been shown to be associated with mortality in ACHBLF.
Eighty patients with ACHBLF were divided into group glucocorticoid (GC) and group conservative medical (CM). Sixty patients with chronic hepatitis B (CHB), and Thirty healthy controls (HCs) served as control group. SOCS1 methylation levels in peripheral mononuclear cells (PBMCs) was detected by MethyLight.
SOCS1 methylation levels were significantly higher in patients with ACHBLF than those with CHB and HCs (P < 0.01, respectively). Nonsurvivors showed significantly higher SOCS1 methylation levels (P < 0.05) than survivors in both GC and CM groups in ACHBLF patients. Furthermore, the survival rates of the SOCS1 methylation-negative group were significantly higher than that of the methylation-positive group at 1 month (P = 0.014) and 3 months (P = 0.003) follow-up. Meanwhile, GC group and CM group had significantly lower mortality at 3 months, which may be related to application of glucocorticoid. In the SOCS1 methylation-positive group, the 1-month survival rate was significantly improved, which may be related to GC treatment (P = 0.020). However, no significant difference could be observed between the GC group and CM group in the methylation-negative group (P = 0.190).
GC treatment could decrease the mortality of ACHBLF and SOCS1 methylation levels might serve as prognostic marker for favorable response to glucocorticoid treatment.
糖皮质激素可以极大地改善慢性乙型肝炎慢加急性肝衰竭（ACHBLF）患者的预后。抑制细胞因子信号（SOCS）1 甲基化已被证明与 ACHBLF 的死亡率有关。
将 80 例 ACHBLF 患者分为糖皮质激素（GC）组和保守治疗（CM）组。60 例慢性乙型肝炎（CHB）患者和 30 例健康对照（HCs）作为对照组。采用 MethyLight 法检测外周血单个核细胞（PBMCs）中 SOCS1 甲基化水平。
ACHBLF 患者 SOCS1 甲基化水平明显高于 CHB 患者和 HCs（P<0.01）。ACHBLF 患者 GC 组和 CM 组中，死亡患者 SOCS1 甲基化水平明显高于存活患者（P<0.05）。此外，SOCS1 甲基化阴性组的 1 个月（P=0.014）和 3 个月（P=0.003）随访生存率明显高于甲基化阳性组。同时，GC 组和 CM 组在 3 个月时死亡率明显降低，这可能与糖皮质激素的应用有关。在 SOCS1 甲基化阳性组中，1 个月的生存率明显提高，这可能与 GC 治疗有关（P=0.020）。然而，在 SOCS1 甲基化阴性组中，GC 组和 CM 组之间无显著差异（P=0.190）。
GC 治疗可降低 ACHBLF 的死亡率，SOCS1 甲基化水平可能作为对糖皮质激素治疗反应良好的预后标志物。
Zotero 插件
